Mapping inflammation onto mood: Inflammatory mediators of anhedonia

Neuroscience and Biobehavioral Reviews

Volumn 64, Issue , 2016, Pages 148-166

  Swardfager, Walter ^a,b,c   Rosenblat, Joshua D ^a,d   Benlamri, Meriem ^a   McIntyre, Roger S ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sunnybrook Health Sciences Centre   (Canada)

^c TORONTO REHABILITATION INSTITUTE   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anhedonia; Cytokine; Depression; Dopamine; Inflammation; Research Domain Criteria; Reward

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIBIOTIC AGENT; CATECHOLAMINE; DOPAMINE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; TETRAHYDROBIOPTERIN; TUMOR NECROSIS FACTOR; CYTOKINE;

AGING; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANHEDONIA; AUTOIMMUNITY; BASAL GANGLION; BIPOLAR DISORDER; BRAIN MAPPING; CATECHOLAMINERGIC SYSTEM; CEREBROVASCULAR ACCIDENT; CINGULATE GYRUS; DIAGNOSTIC TEST; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; INFECTION; INFLAMMATION; INSULA; LIMBIC SYSTEM; MAJOR DEPRESSION; MOOD; MOOD DISORDER; NERVE CELL NETWORK; NERVOUS SYSTEM INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORBITAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ANIMAL; BRAIN; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANHEDONIA; ANIMALS; BRAIN; CYTOKINES; HUMANS;

EID: 84959486870     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2016.02.017     Document Type: Review

References (227)

1. Abbasi S.H., Hosseini F., Modabbernia A., Ashrafi M., Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J. Affect. Disord. 2012, 141:308-314. 10.1016/j.jad.2012.03.033.
2. Abeywardena M.Y., Leifert W.R., Warnes K.E., Varghese J.N., Head R.J. Cardiovascular biology of interleukin-6. Curr. Pharm. Des. 2009, 15:1809-1821.
3. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., Mohebbi-Rasa S., Raznahan M., Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 2009, 26:607-611. 10.1002/da.20589.
4. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., Mcgeer P.L., O'banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
5. Amori L., Guidetti P., Pellicciari R., Kajii Y., Schwarcz R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J. Neurochem. 2009, 109:316-325. 10.1111/j.1471-4159.2009.05893.x.
6. Anisman H., Kokkinidis L., Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav. Immun. 2002, 16:544-556.
7. Anisman H., Matheson K. Stress, depression, and anhedonia: caveats concerning animal models. Neurosci. Biobehav. Rev. 2005, 29:525-546. 10.1016/j.neubiorev.2005.03.007.
8. Appels A., Bar F.W., Bar J., Bruggeman C., De Baets M. Inflammation, depressive symptomtology, and coronary artery disease. Psychosom. Med. 2000, 62:601-605.
9. Assogna F., Cravello L., Caltagirone C., Spalletta G. Anhedonia in Parkinson's disease: a systematic review of the literature. Mov. Disord. 2011, 26:1825-1834. 10.1002/mds.23815.
10. Baik J.H. Dopamine signaling in reward-related behaviors. Front. Neural Circuits 2013, 7:152. 10.3389/fncir.2013.00152.
11. Banks W.A., Erickson M.A. The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 2010, 37:26-32. 10.1016/j.nbd.2009.07.031.
12. Barefoot J.C., Helms M.J., Mark D.B., Blumenthal J.A., Califf R.M., Haney T.L., O'connor C.M., Siegler I.C., Williams R.B. Depression and long-term mortality risk in patients with coronary artery disease. Am. J. Cardiol. 1996, 78:613-617.
13. Barth J., Schumacher M., Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom. Med. 2004, 66:802-813. 10.1097/01.psy.0000146332.53619.b2.
14. Bedwell J.S., Gooding D.C., Chan C.C., Trachik B.J. Anhedonia in the age of RDoC. Schizophr. Res. 2014, 160:226-227. 10.1016/j.schres.2014.10.028.
15. Beggiato S., Antonelli T., Tomasini M.C., Tanganelli S., Fuxe K., Schwarcz R., Ferraro L. Kynurenic acid, by targeting alpha7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo. Eur. J. Neurosci. 2013, 37:1470-1477. 10.1111/ejn.12160.
16. Benros M.E., Waltoft B.L., Nordentoft M., Ostergaard S.D., Eaton W.W., Krogh J., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 2013, 70:812-820. 10.1001/jamapsychiatry.2013.1111.
17. Bensimon K., Herrmann N., Swardfager W., Yi H., Black S.E., Gao F.Q., Snaiderman A., Lanctot K.L. Kynurenine and depressive symptoms in a poststroke population. Neuropsychiatr. Dis. Treat. 2014, 10:1827-1835. 10.2147/NDT.S65740.
18. Berk M., Dean O., Drexhage H., Mcneil J.J., Moylan S., O'neil A., Davey C.G., Sanna L., Maes M. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013, 11:74. 10.1186/1741-7015-11-74.
19. Berlin I., Givry-Steiner L., Lecrubier Y., Puech A.J. Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. Eur. Psychiatry 1998, 13:303-309. 10.1016/S0924-9338(98)80048-5.
20. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Brain Res. Rev. 1998, 28:309-369.
21. Boyer P., Tassin J.P., Falissart B., Troy S. Sequential improvement of anxiety: depression and anhedonia with sertraline treatment in patients with major depression. J. Clin. Pharm. Ther. 2000, 25:363-371.
22. Brebner K., Hayley S., Zacharko R., Merali Z., Anisman H. Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000, 22:566-580. 10.1016/S0893-133X(99)00166-9.
23. Bressa G.M. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol. Scand. Suppl. 1994, 154:7-14.
24. Bressan R.A., Crippa J.A. The role of dopamine in reward and pleasure behaviour-review of data from preclinical research. Acta Psychiatr. Scand. Suppl. 2005, 14-21. 10.1111/j.1600-0447.2005.00540.x.
25. Brietzke E., Mansur R.B., Zugman A., Carvalho A.F., Macedo D.S., Cha D.S., Abilio V.C., Mcintyre R.S. Is there a role for curcumin in the treatment of bipolar disorder?. Med. Hypotheses 2013, 80:606-612. 10.1016/j.mehy.2013.02.001.
26. Briones A., Gagno S., Martisova E., Dobarro M., Aisa B., Solas M., Tordera R., Ramirez M. Stress-induced anhedonia is associated with an increase in Alzheimer's disease-related markers. Br. J. Pharmacol. 2012, 165:897-907. 10.1111/j.1476-5381.2011.01602.x.
27. Brunzell D.H., Mcintosh J.M. Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology 2012, 37:1134-1143. 10.1038/npp.2011.299.
28. Brydon L., Harrison N.A., Walker C., Steptoe A., Critchley H.D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry 2008, 63:1022-1029. 10.1016/j.biopsych.2007.12.007.
29. Capuron L., Pagnoni G., Drake D.F., Woolwine B.J., Spivey J.R., Crowe R.J., Votaw J.R., Goodman M.M., Miller A.H. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch. Gen. Psychiatry 2012, 69:1044-1053. 10.1001/archgenpsychiatry.2011.2094.
30. Capuron L., Ravaud A., Gualde N., Bosmans E., Dantzer R., Maes M., Neveu P.J. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26:797-808.
31. Capuron L., Schroecksnadel S., Feart C., Aubert A., Higueret D., Barberger-Gateau P., Laye S., Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol. Psychiatry 2011, 70:175-182. 10.1016/j.biopsych.2010.12.006.
32. Chan R.C., Shi Y.F., Lai M.K., Wang Y.N., Wang Y., Kring A.M. The temporal experience of pleasure scale (TEPS): exploration and confirmation of factor structure in a healthy Chinese sample. PLoS One 2012, 7:e35352. 10.1371/journal.pone.0035352.
33. Chen C.Y., Tzeng N.S., Chen Y.C. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen. Hosp. Psychiatry 2010, 32(647):e7-e9. 10.1016/j.genhosppsych.2010.07.001.
34. Ciacci C., Iavarone A., Mazzacca G., De Rosa A. Depressive symptoms in adult coeliac disease. Scand. J. Gastroenterol. 1998, 33:247-250.
35. Collin M., Hakansson-Ovesjo M.L., Misane I., Ogren S.O., Meister B. Decreased 5-HT transporter mRNA in neurons of the dorsal raphe nucleus and behavioral depression in the obese leptin-deficient ob/ob mouse. Brain Res. Mol. Brain Res. 2000, 81:51-61.
36. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 2000, 11:58-65.
37. Craft T.K., Devries A.C. Role of IL-1 in poststroke depressive-like behavior in mice. Biol. Psychiatry 2006, 60:812-818. 10.1016/j.biopsych.2006.03.011.
38. Cross-Disorder Group of the Psychiatric Genomics Consortium Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 381:1371-1379. 10.1016/S0140-6736(12)62129-1.
39. D'mello C., Swain M.G. Liver-brain interactions in inflammatory liver diseases: implications for fatigue and mood disorders. Brain Behav. Immun. 2014, 35:9-20. 10.1016/j.bbi.2013.10.009.
40. Damen N.L., Pelle A.J., Boersma E., Serruys P.W., Van Domburg R.T., Pedersen S.S. Reduced positive affect (anhedonia) is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention: results from the RESEARCH registry. Eur. J. Prev. Cardiol. 2013, 20:127-134. 10.1177/2047487312436452.
41. Dantzer R., Bluthe R.M., Gheusi G., Cremona S., Laye S., Parnet P., Kelley K.W. Molecular basis of sickness behavior. Ann. N. Y. Acad. Sci. 1998, 856:132-138.
42. Dantzer R., O'connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56. 10.1038/nrn2297.
43. Dantzer R., O'connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436. 10.1016/j.psyneuen.2010.09.012.
44. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
45. Davidson K.W., Burg M.M., Kronish I.M., Shimbo D., Dettenborn L., Mehran R., Vorchheimer D., Clemow L., Schwartz J.E., Lesperance F., Rieckmann N. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch. Gen. Psychiatry 2010, 67:480-488. 10.1001/archgenpsychiatry.2010.36.
46. De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272. 10.2337/db13-1954.
47. De Luca C., Olefsky J.M. Inflammation and insulin resistance. FEBS Lett. 2008, 582:97-105. 10.1016/j.febslet.2007.11.057.
48. De Souza C.T., Araujo E.P., Bordin S., Ashimine R., Zollner R.L., Boschero A.C., Saad M.J., Velloso L.A. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 2005, 146:4192-4199. 10.1210/en.2004-1520.
49. Deberdt R., Van Hooren J., Amery W. Antinuclear factor: a dysimmunological feature in mental depression. A preliminary communication. Psychother. Psychosom. 1974, 24:119-122.
50. Denollet J., Pedersen S.S., Daemen J., De Jaegere P., Serruys P.W., Van Domburg R.T. Reduced positive affect (anhedonia) predicts major clinical events following implantation of coronary-artery stents. J. Intern. Med. 2008, 263:203-211. 10.1111/j.1365-2796.2007.01870.x.
51. Dichter G.S., Smoski M.J., Kampov-Polevoy A.B., Gallop R., Garbutt J.C. Unipolar depression does not moderate responses to the Sweet Taste Test. Depress. Anxiety 2010, 27:859-863. 10.1002/da.20690.
52. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Alaedini A., Yolken R. Markers of gluten sensitivity and celiac disease in bipolar disorder. Bipolar Disord. 2011, 13:52-58. 10.1111/j.1399-5618.2011.00894.x.
53. Dilger R.N., Johnson R.W. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J. Leukoc. Biol. 2008, 84:932-939. 10.1189/jlb.0208108.
54. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457. 10.1016/j.biopsych.2009.09.033.
55. Drake C., Boutin H., Jones M.S., Denes A., Mccoll B.W., Selvarajah J.R., Hulme S., Georgiou R.F., Hinz R., Gerhard A., Vail A., Prenant C., Julyan P., Maroy R., Brown G., Smigova A., Herholz K., Kassiou M., Crossman D., Francis S., Proctor S.D., Russell J.C., Hopkins S.J., Tyrrell P.J., Rothwell N.J., Allan S.M. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav. Immun. 2011, 25:1113-1122. 10.1016/j.bbi.2011.02.008.
56. Eisenberger N.I., Berkman E.T., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry 2010, 68:748-754. 10.1016/j.biopsych.2010.06.010.
57. Eller T., Vasar V., Shlik J., Maron E. The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr. Opin. Investig. Drugs 2009, 10:638-643.
58. Ertenli I., Ozer S., Kiraz S., Apras S.B., Akdogan A., Karadag O., Calguneri M., Kalyoncu U. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol. Int. 2012, 32:323-330. 10.1007/s00296-010-1616-x.
59. Etain B., Roy I., Henry C., Rousseva A., Schurhoff F., Leboyer M., Bellivier F. No evidence for physical anhedonia as a candidate symptom or an endophenotype in bipolar affective disorder. Bipolar Disord. 2007, 9:706-712. 10.1111/j.1399-5618.2007.00413.x.
60. Fava M., Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J. Clin. Psychiatry 2009, 70(Suppl. 5). 12-7. 10.4088/JCP.8157su1c.03.
61. Fawcett J., Scheftner W.A., Fogg L., Clark D.C., Young M.A., Hedeker D., Gibbons R. Time-related predictors of suicide in major affective disorder. Am. J. Psychiatry 1990, 147:1189-1194.
62. Feldman S.R., Gottlieb A.B., Bala M., Wu Y., Eisenberg D., Guzzo C., Li S., Dooley L.T., Menter A. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br. J. Dermatol. 2008, 159:704-710. 10.1111/j.1365-2133.2008.08727.x.
63. Felger J.C., Alagbe O., Hu F., Mook D., Freeman A.A., Sanchez M.M., Kalin N.H., Ratti E., Nemeroff C.B., Miller A.H. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol. Psychiatry 2007, 62:1324-1333. 10.1016/j.biopsych.2007.05.026.
64. Felger J.C., Li Z., Haroon E., Woolwine B.J., Jung M.Y., Hu X., Miller A.H. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry 2015, 10.1038/mp.2015.168.
65. Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front. Neuroendocrinol. 2012, 33:315-327. 10.1016/j.yfrne.2012.09.003.
66. Felger J.C., Mun J., Kimmel H.L., Nye J.A., Drake D.F., Hernandez C.R., Freeman A.A., Rye D.B., Goodman M.M., Howell L.L., Miller A.H. Chronic interferon-alpha decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology 2013, 38:2179-2187. 10.1038/npp.2013.115.
67. Frenois F., Moreau M., O'connor J., Lawson M., Micon C., Lestage J., Kelley K.W., Dantzer R., Castanon N. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531. 10.1016/j.psyneuen.2007.03.005.
68. Gabbay V., Ely B.A., Babb J., Liebes L. The possible role of the kynurenine pathway in anhedonia in adolescents. J. Neural Transm. 2012, 119:253-260. 10.1007/s00702-011-0685-7.
69. Garate I., Garcia-Bueno B., Madrigal J.L., Caso J.R., Alou L., Gomez-Lus M.L., Mico J.A., Leza J.C. Stress-induced neuroinflammation: role of the toll-like receptor-4 pathway. Biol. Psychiatry 2013, 73:32-43. 10.1016/j.biopsych.2012.07.005.
70. Garfield J.B., Lubman D.I., Yucel M. Anhedonia in substance use disorders: a systematic review of its nature, course and clinical correlates. Aust. N. Z. J. Psychiatry 2014, 48:36-51. 10.1177/0004867413508455.
71. Gibney S.M., Mcguinness B., Prendergast C., Harkin A., Connor T.J. Poly I: C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav. Immun. 2013, 28:170-181. 10.1016/j.bbi.2012.11.010.
72. Gilbody S., Lightfoot T., Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J. Epidemiol. Community Health 2007, 61:631-637. 10.1136/jech.2006.050385.
73. Goldberg J.F., Burdick K.E., Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry 2004, 161:564-566.
74. Goldstein B.I., Kemp D.E., Soczynska J.K., Mcintyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70:1078-1090. 10.4088/JCP.08r04505.
75. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin. Neurosci. 2008, 10:291-299.
76. Grillo C.A., Mulder P., Macht V.A., Kaigler K.F., Wilson S.P., Wilson M.A., Reagan L.P. Dietary restriction reverses obesity-induced anhedonia. Physiol. Behav. 2014, 128:126-132. 10.1016/j.physbeh.2014.01.026.
77. Grillo C.A., Piroli G.G., Evans A.N., Macht V.A., Wilson S.P., Scott K.A., Sakai R.R., Mott D.D., Reagan L.P. Obesity/hyperleptinemic phenotype adversely affects hippocampal plasticity: effects of dietary restriction. Physiol. Behav. 2011, 104:235-241. 10.1016/j.physbeh.2010.10.020.
78. Grillo C.A., Piroli G.G., Junor L., Wilson S.P., Mott D.D., Wilson M.A., Reagan L.P. Obesity/hyperleptinemic phenotype impairs structural and functional plasticity in the rat hippocampus. Physiol. Behav. 2011, 105:138-144. 10.1016/j.physbeh.2011.02.028.
79. Grillo C.A., Piroli G.G., Kaigler K.F., Wilson S.P., Wilson M.A., Reagan L.P. Downregulation of hypothalamic insulin receptor expression elicits depressive-like behaviors in rats. Behav. Brain Res. 2011, 222:230-235. 10.1016/j.bbr.2011.03.052.
80. Grosso G., Pajak A., Marventano S., Castellano S., Galvano F., Bucolo C., Drago F., Caraci F. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014, 9:e96905. 10.1371/journal.pone.0096905.
81. Hannestad J., Gallezot J.D., Schafbauer T., Lim K., Kloczynski T., Morris E.D., Carson R.E., Ding Y.S., Cosgrove K.P. Endotoxin-induced systemic inflammation activates microglia: [(1)(1)C]PBR28 positron emission tomography in nonhuman primates. Neuroimage 2012, 63:232-239. 10.1016/j.neuroimage.2012.06.055.
82. Hannestad J., Subramanyam K., Dellagioia N., Planeta-Wilson B., Weinzimmer D., Pittman B., Carson R.E. Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans. J. Nucl. Med. 2012, 53:601-607. 10.2967/jnumed.111.097014.
83. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66:407-414. 10.1016/j.biopsych.2009.03.015.
84. Hart B.L. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 1988, 12:123-137.
85. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., Sheridan J.F., Godbout J.P. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation 2008, 5:15. 10.1186/1742-2094-5-15.
86. Hepgul N., Cattaneo A., Zunszain P.A., Pariante C.M. Depression pathogenesis and treatment: what can we learn from blood mRNA expression?. BMC Med. 2013, 11:28. 10.1186/1741-7015-11-28.
87. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 2001, 21:7463-7473.
88. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186. 10.1097/PSY.0b013e3181907c1b.
89. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186. 10.1097/PSY.0b013e3181907c1b.
90. Iadecola C., Anrather J. The immunology of stroke: from mechanisms to translation. Nat. Med. 2011, 17:796-808. 10.1038/nm.2399.
91. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 2007, 56:27-78.
92. International Schizophrenia Consortium, Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752. 10.1038/nature08185.
93. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol. Life Sci. 2004, 61:470-487. 10.1007/s00018-003-3204-7.
94. Janes A.C., Pedrelli P., Whitton A.E., Pechtel P., Douglas S., Martinson M.A., Huz I., Fava M., Pizzagalli D.A., Evins A.E. Reward responsiveness varies by smoking status in women with a history of major depressive disorder. Neuropsychopharmacology 2015, 40:1940-1946. 10.1038/npp.2015.43.
95. Keller J., Young C.B., Kelley E., Prater K., Levitin D.J., Menon V. Trait anhedonia is associated with reduced reactivity and connectivity of mesolimbic and paralimbic reward pathways. J. Psychiatr. Res. 2013, 47:1319-1328. 10.1016/j.jpsychires.2013.05.015.
96. Kelley K.W., O'connor J.C., Lawson M.A., Dantzer R., Rodriguez-Zas S.L., Mccusker R.H. Aging leads to prolonged duration of inflammation-induced depression-like behavior caused by Bacillus Calmette-Guerin. Brain Behav. Immun. 2013, 32:63-69. 10.1016/j.bbi.2013.02.003.
97. Kennerley S.W., Dahmubed A.F., Lara A.H., Wallis J.D. Neurons in the frontal lobe encode the value of multiple decision variables. J. Cogn. Neurosci. 2009, 21:1162-1178. 10.1162/jocn.2009.21100.
98. Kim H., Chen L., Lim G., Sung B., Wang S., Mccab M.F., Rusanescu G., Yang L., Tian Y., Mao J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 2012, 122:2940-2954. 10.1172/JCI61884.
99. Kleinridders A., Cai W., Cappellucci L., Ghazarian A., Collins W.R., Vienberg S.G., Pothos E.N., Kahn C.R. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:3463-3468. 10.1073/pnas.1500877112.
100. Kohler O., Benros M.E., Nordentoft M., Farkouh M.E., Iyengar R.L., Mors O., Krogh J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014, 10.1001/jamapsychiatry.2014.1611.
101. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:751-756. 10.1073/pnas.0708092105.
102. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annu. Rev. Psychol. 2008, 59:29-53. 10.1146/annurev.psych.59.103006.093548.
103. Koolschijn P.C., Van Haren N.E., Lensvelt-Mulders G.J., Hulshoff Pol H.E., Kahn R.S. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum. Brain Mapp. 2009, 30:3719-3735. 10.1002/hbm.20801.
104. Koziorowski D., Tomasiuk R., Szlufik S., Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 2012, 60:762-766. 10.1016/j.cyto.2012.07.030.
105. Krishnan R., Cella D., Leonardi C., Papp K., Gottlieb A.B., Dunn M., Chiou C.F., Patel V., Jahreis A. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br. J. Dermatol. 2007, 157:1275-1277. 10.1111/j.1365-2133.2007.08205.x.
106. Kronenberg G., Balkaya M., Prinz V., Gertz K., Ji S., Kirste I., Heuser I., Kampmann B., Hellmann-Regen J., Gass P., Sohr R., Hellweg R., Waeber C., Juckel G., Hortnagl H., Stumm R., Endres M. Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biol. Psychiatry 2012, 72:273-281. 10.1016/j.biopsych.2012.02.026.
107. Kullmann J.S., Grigoleit J.S., Lichte P., Kobbe P., Rosenberger C., Banner C., Wolf O.T., Engler H., Oberbeck R., Elsenbruch S., Bingel U., Forsting M., Gizewski E.R., Schedlowski M. Neural response to emotional stimuli during experimental human endotoxemia. Hum. Brain Mapp. 2013, 34:2217-2227. 10.1002/hbm.22063.
108. Lally N., Nugent A.C., Luckenbaugh D.A., Ameli R., Roiser J.P., Zarate C.A. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 2014, 4:e469. 10.1038/tp.2014.105.
109. Lamers F., Vogelzangs N., Merikangas K.R., De Jonge P., Beekman A.T., Penninx B.W. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol. Psychiatry 2013, 18:692-699. 10.1038/mp.2012.144.
110. Langley R.G., Feldman S.R., Han C., Schenkel B., Szapary P., Hsu M.C., Ortonne J.P., Gordon K.B., Kimball A.B. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J. Am. Acad. Dermatol. 2010, 63:457-465. 10.1016/j.jaad.2009.09.014.
111. Lapteva L., Nowak M., Yarboro C.H., Takada K., Roebuck-Spencer T., Weickert T., Bleiberg J., Rosenstein D., Pao M., Patronas N., Steele S., Manzano M., Van Der Veen J.W., Lipsky P.E., Marenco S., Wesley R., Volpe B., Diamond B., Illei G.G. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2505-2514. 10.1002/art.22031.
112. Laske C., Zank M., Klein R., Stransky E., Batra A., Buchkremer G., Schott K. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res. 2008, 158:83-86. 10.1016/j.psychres.2006.04.023.
113. Legros S., Mendlewicz J., Wybran J. Immunoglobulins: autoantibodies and other serum protein fractions in psychiatric disorders. Eur. Arch. Psychiatry Neurol. Sci. 1985, 235:9-11.
114. Levitt A.J., Joffe R.T. Folate, B12, and life course of depressive illness. Biol. Psychiatry 1989, 25:867-872.
115. Li W., Knowlton D., Woodward W.R., Habecker B.A. Regulation of noradrenergic function by inflammatory cytokines and depolarization. J. Neurochem. 2003, 86:774-783.
116. Libby P., Ridker P.M., Hansson G.K., Leducq Transatlantic Network On Atherothrombosis Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009, 54:2129-2138. 10.1016/j.jacc.2009.09.009.
117. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
118. Ligthart S.A., Richard E., Fransen N.L., Eurelings L.S., Beem L., Eikelenboom P., Van Gool W.A., Moll Van Charante E.P. Association of vascular factors with apathy in community-dwelling elderly individuals. Arch. Gen. Psychiatry 2012, 69:636-642. 10.1001/archgenpsychiatry.2011.1858.
119. Liu Y., Ho R.C., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord. 2012, 139:230-239. 10.1016/j.jad.2011.08.003.
120. Loas G., Krystkowiak P., Godefroy O. Anhedonia in Parkinson's disease: an overview. J. Neuropsychiatry Clin. Neurosci. 2012, 24:444-451. 10.1176/appi.neuropsych.11110332.
121. Lopresti A.L., Hood S.D., Drummond P.D. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J. Psychopharmacol. 2012, 26:1512-1524. 10.1177/0269881112458732.
122. Lopresti A.L., Maes M., Maker G.L., Hood S.D., Drummond P.D. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J. Affect. Disord. 2014, 167:368-375. 10.1016/j.jad.2014.06.001.
123. Louveau A., Smirnov I., Keyes T.J., Eccles J.D., Rouhani S.J., Peske J.D., Derecki N.C., Castle D., Mandell J.W., Lee K.S., Harris T.H., Kipnis J. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523:337-341. 10.1038/nature14432.
124. Lu X.Y., Kim C.S., Frazer A., Zhang W. Leptin: a potential novel antidepressant. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1593-1598. 10.1073/pnas.0508901103.
125. Luppino F.S., De Wit L.M., Bouvy P.F., Stijnen T., Cuijpers P., Penninx B.W., Zitman F.G. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 2010, 67:220-229. 10.1001/archgenpsychiatry.2010.2.
126. Lyngso D., Simonsen L., Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J. Physiol. 2002, 543:379-386.
127. Macchi B., Di Paola R., Marino-Merlo F., Felice M.R., Cuzzocrea S., Mastino A. Inflammatory and cell death pathways in brain and peripheral blood in Parkinson's disease. CNS Neurol. Disord. Drug Targets 2015, 14:313-324.
128. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:664-675. 10.1016/j.pnpbp.2010.06.014.
129. Maes M., Bosmans E., Scharpe S., D'hondt P., Desnyder R. Plasma soluble interleukin-2-receptor in depression: relationships to plasma neopterin and serum IL-2 concentrations and HPA-axis activity. Eur. Psychiatry 1995, 10:397-403. 10.1016/0924-9338(96) 80345-2.
130. Maes M., Bosmans E., Suy E., Vandervorst C., Dejonckheere C., Raus J. Antiphospholipid, antinuclear, Epstein-Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients. J. Affect. Disord. 1991, 21:133-140.
131. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J. Affect. Disord. 2010, 125:287-294. 10.1016/j.jad.2009.12.014.
132. Maletic V., Raison C. Integrated neurobiology of bipolar disorder. Front. Psychiatry 2014, 5:98. 10.3389/fpsyt.2014.00098.
133. Mansvelder H.D., De Rover M., Mcgehee D.S., Brussaard A.B. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur. J. Pharmacol. 2003, 480:117-123.
134. Mathieu P., Lemieux I., Despres J.P. Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 2010, 87:407-416. 10.1038/clpt.2009.311.
135. Mathieu P., Pibarot P., Larose E., Poirier P., Marette A., Despres J.P. Visceral obesity and the heart. Int. J. Biochem. Cell Biol. 2008, 40:821-836. 10.1016/j.biocel.2007.12.001.
136. Mazza M., Squillacioti M.R., Pecora R.D., Janiri L., Bria P. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients. Psychiatry Res. 2009, 165:193-196. 10.1016/j.psychres.2008.05.003.
137. Mcfarland B.R., Shankman S.A., Tenke C.E., Bruder G.E., Klein D.N. Behavioral activation system deficits predict the six-month course of depression. J. Affect. Disord. 2006, 91:229-234. 10.1016/j.jad.2006.01.012.
138. Mcmakin D.L., Olino T.M., Porta G., Dietz L.J., Emslie G., Clarke G., Wagner K.D., Asarnow J.R., Ryan N.D., Birmaher B., Shamseddeen W., Mayes T., Kennard B., Spirito A., Keller M., Lynch F.L., Dickerson J.F., Brent D.A. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J. Am. Acad. Child Adolesc. Psychiatry 2012, 51:404-411. 10.1016/j.jaac.2012.01.011.
139. Mcnamara R.K., Strawn J.R. Role of long-chain omega-3 fatty acids in psychiatric practice. PharmaNutrition 2013, 1:41-49. 10.1016/j.phanu.2012.10.004.
140. Mello B.S., Monte A.S., Mcintyre R.S., Soczynska J.K., Custodio C.S., Cordeiro R.C., Chaves J.H., Vasconcelos S.M., Nobre H.V., Florenco De Sousa F.C., Hyphantis T.N., Carvalho A.F., Macedo D.S. Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J. Psychiatr. Res. 2013, 47:1521-1529. 10.1016/j.jpsychires.2013.06.008.
141. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671. 10.1016/j.biopsych.2011.04.013.
142. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 2013, 74:15-25. 10.1016/j.biopsych.2013.01.007.
143. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
144. Monteggia L.M., Gideons E., Kavalali E.T. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol. Psychiatry 2013, 73:1199-1203. 10.1016/j.biopsych.2012.09.006.
145. Moreau M., Andre C., O'connor J.C., Dumich S.A., Woods J.A., Kelley K.W., Dantzer R., Lestage J., Castanon N. Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav. Immun. 2008, 22:1087-1095. 10.1016/j.bbi.2008.04.001.
146. Muller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs 2010, 11:31-42.
147. Murr C., Widner B., Wirleitner B., Fuchs D. Neopterin as a marker for immune system activation. Curr. Drug Metab. 2002, 3:175-187.
148. Myint A.M., Steinbusch H.W., Goeghegan L., Luchtman D., Kim Y.K., Leonard B.E. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007, 14:65-71. 10.1159/000107420.
149. Natta L., Melrose R., Harwood D., Sultzer D. An examination of anhedonia separate from depression in Alzheimer's disease: a preliminary study. Am. J. Geriatr. Psychiatry 2013, 21(Suppl):S78-S79.
150. National Institute of Mental Health, 2011. Positive Valence Systems: Workshop Proceedings. Retrieved from (accessed 2015). http://www.nimh.nih.gov/research-priorities/rdoc/positive-valence-systems-workshop-proceedings.shtml.
151. Nefs G., Pouwer F., Denollet J., Kramer H., Wijnands-Van Gent C.J., Pop V.J. Suboptimal glycemic control in type 2 diabetes: a key role for anhedonia?. J. Psychiatr. Res. 2012, 46:549-554. 10.1016/j.jpsychires.2012.01.013.
152. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., Bowden C.L., Soares J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 2008, 23:87-94. 10.1002/hup.912.
153. Network Pathway Analysis Subgroup of Psychiatric Genomics Consortium Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. 2015, 18:199-209. 10.1038/nn.3922.
154. Neurauter G., Schrocksnadel K., Scholl-Burgi S., Sperner-Unterweger B., Schubert C., Ledochowski M., Fuchs D. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr. Drug Metab. 2008, 9:622-627.
155. Nguyen M.T., Favelyukis S., Nguyen A.K., Reichart D., Scott P.A., Jenn A., Liu-Bryan R., Glass C.K., Neels J.G., Olefsky J.M. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 2007, 282:35279-35292. 10.1074/jbc.M706762200.
156. Noonan M.P., Kolling N., Walton M.E., Rushworth M.F. Re-evaluating the role of the orbitofrontal cortex in reward and reinforcement. Eur. J. Neurosci. 2012, 35:997-1010. 10.1111/j.1460-9568.2012.08023.x.
157. Nutt D., Demyttenaere K., Janka Z., Aarre T., Bourin M., Canonico P.L., Carrasco J.L., Stahl S. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J. Psychopharmacol. 2007, 21:461-471. 10.1177/0269881106069938.
158. O'connor J.C., Andre C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., Castanon N., Kelley K.W., Dantzer R. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J. Neurosci. 2009, 29:4200-4209. 10.1523/JNEUROSCI.5032-08.2009.
159. O'connor J.C., Lawson M.A., Andre C., Briley E.M., Szegedi S.S., Lestage J., Castanon N., Herkenham M., Dantzer R., Kelley K.W. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J. Immunol. 2009, 182:3202-3212. 10.4049/jimmunol.0802722.
160. O'leary O.F., Bechtholt A.J., Crowley J.J., Hill T.E., Page M.E., Lucki I. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl.) 2007, 192:357-371. 10.1007/s00213-007-0728-9.
161. Orr C.F., Rowe D.B., Halliday G.M. An inflammatory review of Parkinson's disease. Prog. Neurobiol. 2002, 68:325-340.
162. Papakostas G.I., Shelton R.C., Zajecka J.M., Bottiglieri T., Roffman J., Cassiello C., Stahl S.M., Fava M. Effect of adjunctive l-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J. Clin. Psychiatry 2014, 75:855-863. 10.4088/JCP.13m08947.
163. Papakostas G.I., Shelton R.C., Zajecka J.M., Etemad B., Rickels K., Clain A., Baer L., Dalton E.D., Sacco G.R., Schoenfeld D., Pencina M., Meisner A., Bottiglieri T., Nelson E., Mischoulon D., Alpert J.E., Barbee J.G., Zisook S., Fava M. l-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am. J. Psychiatry 2012, 169:1267-1274. 10.1176/appi.ajp.2012.11071114.
164. Pearlman D.M., Najjar S. Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr. Res 2014, 157:249-258. 10.1016/j.schres.2014.05.001.
165. Pelle A.J., Pedersen S.S., Erdman R.A., Kazemier M., Spiering M., Van Domburg R.T., Denollet J. Anhedonia is associated with poor health status and more somatic and cognitive symptoms in patients with coronary artery disease. Qual. Life Res. 2011, 20:643-651. 10.1007/s11136-010-9792-4.
166. Persoons P., Vermeire S., Demyttenaere K., Fischler B., Vandenberghe J., Van Oudenhove L., Pierik M., Hlavaty T., Van Assche G., Noman M., Rutgeerts P. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol. Ther. 2005, 22:101-110. 10.1111/j.1365-2036.2005.02535.x.
167. Ploder M., Neurauter G., Spittler A., Schroecksnadel K., Roth E., Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids 2008, 35:303-307. 10.1007/s00726-007-0625-x.
168. Pollak Y., Ovadia H., Orion E., Weidenfeld J., Yirmiya R. The EAE-associated behavioral syndrome: I. Temporal correlation with inflammatory mediators. J. Neuroimmunol. 2003, 137:94-99.
169. Pollak Y., Ovadia H., Orion E., Yirmiya R. The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments. J. Neuroimmunol. 2003, 137:100-108.
170. Quaranta D., Marra C., Gainotti G. Post-stroke depression: main phenomenological clusters and their relationships with clinical measures. Behav. Neurol. 2012, 25:303-310. 10.3233/BEN-2012-110236.
171. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41. 10.1001/2013.jamapsychiatry.4.
172. Revelo X.S., Tsai S., Lei H., Luck H., Ghazarian M., Tsui H., Shi S.Y., Schroer S., Luk C.T., Lin G.H., Mak T.W., Woo M., Winer S., Winer D.A. Perforin is a novel immune regulator of obesity-related insulin resistance. Diabetes 2015, 64:90-103. 10.2337/db13-1524.
173. Richardson M.A., Read L.L., Reilly M.A., Clelland J.D., Clelland C.L. Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder. Neurochem. Res. 2007, 32:107-113. 10.1007/s11064-006-9233-5.
174. Richardson M.A., Read L.L., Taylor Clelland C.L., Reilly M.A., Chao H.M., Guynn R.W., Suckow R.F., Clelland J.D. Evidence for a tetrahydrobiopterin deficit in schizophrenia. Neuropsychobiology 2005, 52:190-201. 10.1159/000089002.
175. Ritsner M.S., Arbitman M., Lisker A. Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder. J. Nerv. Ment. Dis. 2011, 199:845-853. 10.1097/NMD.0b013e3182349ce6.
176. Rizzo L.B., Costa L.G., Mansur R.B., Swardfager W., Belangero S.I., Grassi-Oliveira R., Mcintyre R.S., Bauer M.E., Brietzke E. The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research. Neurosci. Biobehav. Rev. 2014, 42:157-169. 10.1016/j.neubiorev.2014.02.004.
177. Rolls E.T. The orbitofrontal cortex and reward. Cereb Cortex 2000, 10:284-294.
178. Romer Thomsen K., Whybrow P.C., Kringelbach M.L. Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. Front. Behav. Neurosci. 2015, 9:49. 10.3389/fnbeh.2015.00049.
179. Rosenblat J.D., Cha D.S., Mansur R.B., Mcintyre R.S. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 53:23-34. 10.1016/j.pnpbp.2014.01.013.
180. Rotella F., Mannucci E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res. Clin. Pract. 2013, 99:98-104. 10.1016/j.diabres.2012.11.022.
181. Russo S.J., Nestler E.J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 2013, 14:609-625. 10.1038/nrn3381.
182. Sakic B., Denburg J.A., Denburg S.D., Szechtman H. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve-shift study. Brain Res. Bull. 1996, 41:305-311.
183. Salamone J.D., Correa M., Mingote S., Weber S.M. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J. Pharmacol. Exp. Ther. 2003, 305:1-8. 10.1124/jpet.102.035063.
184. Salamone J.D., Pardo M., Yohn S.E., Lopez-Cruz L., Sanmiguel N., Correa M. Mesolimbic dopamine and the regulation of motivated behavior. Curr. Top. Behav. Neurosci. 2015, 10.1007/7854_2015_383.
185. Salazar A., Gonzalez-Rivera B.L., Redus L., Parrott J.M., O'connor J.C. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm. Behav. 2012, 62:202-209. 10.1016/j.yhbeh.2012.03.010.
186. Savitz J., Dantzer R., Meier T.B., Wurfel B.E., Victor T.A., Mcintosh S.A., Ford B.N., Morris H.M., Bodurka J., Teague T.K., Drevets W.C. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. Psychoneuroendocrinology 2015, 62:54-58. 10.1016/j.psyneuen.2015.07.609.
187. Savitz J., Drevets W.C., Smith C.M., Victor T.A., Wurfel B.E., Bellgowan P.S., Bodurka J., Teague T.K., Dantzer R. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2015, 40:463-471. 10.1038/npp.2014.194.
188. Sayd A., Anton M., Alen F., Caso J.R., Pavon J., Leza J.C., Rodriguez De Fonseca F., Garcia-Bueno B., Orio L. Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats. Int J Neuropsychopharmacol 2015, 18. 10.1093/ijnp/pyu111.
189. Schizophrenia Psychiatric Genome-Wide Association Study Consortium Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976. 10.1038/ng.940.
190. Setiawan E., Wilson A.A., Mizrahi R., Rusjan P.M., Miler L., Rajkowska G., Suridjan I., Kennedy J.L., Rekkas P.V., Houle S., Meyer J.H. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015, 72:268-275. 10.1001/jamapsychiatry.2014.2427.
191. Sharma A.N., Elased K.M., Garrett T.L., Lucot J.B. Neurobehavioral deficits in db/db diabetic mice. Physiol. Behav. 2010, 101:381-388. 10.1016/j.physbeh.2010.07.002.
192. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757. 10.1038/nature08192.
193. Snaith R.P., Hamilton M., Morley S., Humayan A., Hargreaves D., Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale. Br. J. Psychiatry 1995, 167:99-103.
194. So Y., Kim K., Park J., Lee J., Lee S., Kim T. Anhedonia is associated with the risk of Alzheimer's disease in elders with mild cognitive impairment: results from the Korean Longitudinal Study on Health and Aging (KLOSHA). Alzheimer's Dement. 2012, 8(Suppl):594.
195. Soczynska J.K., Mansur R.B., Brietzke E., Swardfager W., Kennedy S.H., Woldeyohannes H.O., Powell A.M., Manierka M.S., Mcintyre R.S. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav. Brain Res. 2012, 235:302-317. 10.1016/j.bbr.2012.07.026.
196. Spalding K.L., Arner E., Westermark P.O., Bernard S., Buchholz B.A., Bergmann O., Blomqvist L., Hoffstedt J., Naslund E., Britton T., Concha H., Hassan M., Ryden M., Frisen J., Arner P. Dynamics of fat cell turnover in humans. Nature 2008, 453:783-787. 10.1038/nature06902.
197. Spalletta G., Cravello L., Imperiale F., Salani F., Bossu P., Picchetto L., Cao M., Rasura M., Pazzelli F., Orzi F., Caltagirone C., Robinson R.G., Cacciari C. Neuropsychiatric symptoms and interleukin-6 serum levels in acute stroke. J. Neuropsychiatry Clin. Neurosci. 2013, 25:255-263. 10.1176/appi.neuropsych.12120399.
198. Spijker J., Bijl R.V., De Graaf R., Nolen W.A. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr. Scand. 2001, 103:122-130.
199. Su K.P., Wang S.M., Pae C.U. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opin. Invest. Drugs 2013, 10.1517/13543784.2013.836487.
200. Swardfager W., Herrmann N., Andreazza A.C., Swartz R.H., Khan M.M., Black S.E., Lanctot K.L. Poststroke neuropsychiatric symptoms: relationships with IL-17 and oxidative stress. Biomed. Res. Int. 2014, 24521:245210. 10.1155/2014/245210.
201. Swardfager W., Herrmann N., Dowlati Y., Oh P.I., Kiss A., Walker S.E., Lanctot K.L. Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. Psychoneuroendocrinology 2009, 34:1560-1566. 10.1016/j.psyneuen.2009.05.019.
202. Swardfager W., Herrmann N., Marzolini S., Saleem M., Farber S.B., Kiss A., Oh P.I., Lanctot K.L. Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. J. Clin. Psychiatry. 2011, 72:1181-1188. 10.4088/JCP.09m05810blu.
203. Swardfager W., Herrmann N., Mazereeuw G., Goldberger K., Harimoto T., Lanctot K.L. Zinc in depression: a meta-analysis. Biol. Psychiatry 2013, 74:872-878. 10.1016/j.biopsych.2013.05.008.
204. Swardfager W., Herrmann N., Mazereeuw G., Lanctot K.L. Reply to: serum zinc and the risk of depression in men: observations from a 20-year follow-up study. Biol. Psychiatry 2015, 77:e13-e14. 10.1016/j.biopsych.2014.06.006.
205. Swardfager W., Herrmann N., Mcintyre R.S., Mazereeuw G., Goldberger K., Cha D.S., Schwartz Y., Lanctot K.L. Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci. Biobehav. Rev. 2013, 37:911-929. 10.1016/j.neubiorev.2013.03.018.
206. Swardfager W., Lanctot K., Rothenburg L., Wong A., Cappell J., Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 2010, 68:930-941. 10.1016/j.biopsych.2010.06.012.
207. Swardfager W., Lynch M., Dubey S., Nagy P.M. Neuroinflammation mediates synergy between cerebral ischemia and amyloid-beta to cause synaptic depression. J. Neurosci. 2014, 34:13571-13573. 10.1523/JNEUROSCI.3196-14.2014.
208. Swardfager W., Winer D.A., Herrmann N., Winer S., Lanctot K.L. Interleukin-17 in post-stroke neurodegeneration. Neurosci. Biobehav. Rev. 2013, 37:436-447. 10.1016/j.neubiorev.2013.01.021.
209. Tapia-Gonzalez S., Garcia-Segura L.M., Tena-Sempere M., Frago L.M., Castellano J.M., Fuente-Martin E., Garcia-Caceres C., Argente J., Chowen J.A. Activation of microglia in specific hypothalamic nuclei and the cerebellum of adult rats exposed to neonatal overnutrition. J. Neuroendocrinol. 2011, 23:365-370. 10.1111/j.1365-2826.2011.02113.x.
210. Taylor W.D., Aizenstein H.J., Alexopoulos G.S. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol. Psychiatry 2013, 18:963-974. 10.1038/mp.2013.20.
211. Trainor B.C. Stress responses and the mesolimbic dopamine system: social contexts and sex differences. Horm. Behav. 2011, 60:457-469. 10.1016/j.yhbeh.2011.08.013.
212. Treadway M.T. The neurobiology of motivational deficits in depression-an update on candidate pathomechanisms. Curr. Top. Behav. Neurosci. 2015, 10.1007/7854_2015_400.
213. Treadway M.T., Zald D.H. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci. Biobehav. Rev. 2011, 35:537-555. 10.1016/j.neubiorev.2010.06.006.
214. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35. 10.1016/s0140-6736(05)67763-x.
215. Uher R., Perlis R.H., Henigsberg N., Zobel A., Rietschel M., Mors O., Hauser J., Dernovsek M.Z., Souery D., Bajs M., Maier W., Aitchison K.J., Farmer A., Mcguffin P. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012, 42:967-980. 10.1017/S0033291711001905.
216. Unger R.H. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie 2005, 87:57-64. 10.1016/j.biochi.2004.11.014.
217. Van Den Berg I., Franken I.H., Muris P. A new scale for measuring reward responsiveness. Front. Psychol. 2010, 1:239. 10.3389/fpsyg.2010.00239.
218. Ventura R., Cabib S., Puglisi-Allegra S. Genetic susceptibility of mesocortical dopamine to stress determines liability to inhibition of mesoaccumbens dopamine and to behavioral 'despair' in a mouse model of depression. Neuroscience 2002, 115:999-1007.
219. Wanaverbecq N., Semyanov A., Pavlov I., Walker M.C., Kullmann D.M. Cholinergic axons modulate GABAergic signaling among hippocampal interneurons via postsynaptic alpha 7 nicotinic receptors. J. Neurosci. 2007, 27:5683-5693. 10.1523/JNEUROSCI.1732-07.2007.
220. Wang Q., Liu Y., Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl. Neurodegener. 2015, 4:19. 10.1186/s40035-015-0042-0.
221. Whitton A.E., Treadway M.T., Pizzagalli D.A. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr. Opin. Psychiatry 2015, 28:7-12. 10.1097/YCO.0000000000000122.
222. Widner B., Ledochowski M., Fuchs D. Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr. Drug Metab. 2000, 1:193-204.
223. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., Tsui H., Wu P., Davidson M.G., Alonso M.N., Leong H.X., Glassford A., Caimol M., Kenkel J.A., Tedder T.F., Mclaughlin T., Miklos D.B., Dosch H.M., Engleman E.G. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17:610-617. 10.1038/nm.2353.
224. Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., Dorfman R., Wang Y., Zielenski J., Mastronardi F., Maezawa Y., Drucker D.J., Engleman E., Winer D., Dosch H.M. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15:921-929. 10.1038/nm.2001.
225. Yamada N., Katsuura G., Ochi Y., Ebihara K., Kusakabe T., Hosoda K., Nakao K. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 2011, 152:2634-2643. 10.1210/en.2011-0004.
226. Zangerle R., Kurz K., Neurauter G., Kitchen M., Sarcletti M., Fuchs D. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav. Immun. 2010, 24:403-408. 10.1016/j.bbi.2009.11.004.
227. Zarate C.A., Payne J.L., Singh J., Quiroz J.A., Luckenbaugh D.A., Denicoff K.D., Charney D.S., Manji H.K. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry 2004, 56:54-60. 10.1016/j.biopsych.2004.03.013.